All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Should ropeginterferon become SoC for all patients with low-risk PV?
During the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to Tiziano Barbui, L'ospedale Papa Giovanni XXIII, Bergamo, IT. We asked: Should ropeginterferon become standard of care for all patients with low-risk polycythemia vera (PV)?
Hematocrit control is vital in patients with PV, but is phlebotomy necessary to maintain hematocrit target levels? The monopegylated IFNα-2b, ropeginterferon, may reduce the need for phlebotomy. Results from the randomized phase II study comparing ropeginterferon with phlebotomy for the treatment of low-risk PV will be presented at this year's EHA meeting.
Should ropeginterferon become SoC for all patients with low-risk PV?
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox